Cancer
Researchers from the Affiliated Central Hospital of Huzhou University have made a significant discovery in the treatment of gastric cancer. Encapsulating the anticancer compound Heterophyllin B (HB) in mPEG-PLGA-NH nanoparticles (NPs) modified with aPDL1, the team has created a new treatment strategy that shows promise in enhancing the efficacy of
Cancer
The HER2+ gastric cancer market is expected to experience significant growth, driven by a rising incidence of the disease, improved diagnostic protocols, and expanding therapeutic options. Recently, the FDA has approved several therapies, including ENHERTU, OPDIVO, trastuzumab, KEYTRUDA, and AIDIXI, which are further fueling the market growth. Additionally, late-stage clinical
Cancer
Researchers at Fudan University in Shanghai, China, have discovered a potential new therapeutic agent in the fight against gastric cancer. The compound, known as ginsenoside Rh7, has shown remarkable efficacy in suppressing the growth and spread of cancer cells. According to a study published in the International Journal of Medical
Cancer
A study published in the journal Digestive Diseases has found that both Helicobacter pylori infection and positive family history of gastric cancer (FHx) significantly increase the risk of developing significant gastric precancerous conditions (SGPCs) in the stomach. The researchers conducted a cross-sectional study among 761 treatment-naïve adult patients with upper
Cancer
Historical discriminatory policies, such as residential redlining, and current socioeconomic status can significantly impact gastrointestinal (GI) cancer care, resulting in disparities in diagnosis and treatment. A recent study conducted by researchers from Ohio State University investigated how evolving neighborhood characteristics affect the diagnosis and treatment of GI cancer. The findings
Cancer
A new study comparing open, laparoscopic, and robotic gastrectomy techniques in the treatment of gastric cancer has found that minimally invasive surgical methods, particularly robotic gastrectomy, provide a safe and oncologically adequate alternative to open surgery. The research, conducted at the University of Health Sciences in Istanbul, Turkey, analyzed 109
Cancer
Researchers at Islamic Azad University have published new findings on the effectiveness of a combination therapy in treating gastric cancer. The study investigated the effects of arsenic trioxide (ATO), oxaliplatin (OXA), and docetaxel (DOC) on gastric cancer cell lines in vitro. The findings demonstrated that the combination of ATO with
Cancer
Investigators at Southern Medical University have made new findings in gastric cancer, highlighting the application of probiotics and their metabolic byproducts in gastric cancer and colorectal cancer. According to recent population-based studies, gastrointestinal cancers such as gastric cancer and colorectal cancer are on the rise worldwide, making it essential to
Cancer
Pioneering research by investigators at Tehran University of Medical Sciences has made significant progress in understanding the role of inhibitory receptors in the treatment of gastric cancer. By blocking the NK group-2 member-A (NKG2A) receptor, researchers have demonstrated the enhancement of tumor immunity in natural killer (NK) cells, paving the
Cancer
Research conducted at Sichuan Integrative Medicine Hospital in Chengdu, People's Republic of China, has explored the predictive value of certain detection indexes and pathological serum levels in patients with early gastric cancer who underwent radical surgery. The study retrospectively analyzed clinical data of 297 EGC patients admitted to
Cancer
The HER2 Positive Gastric Cancer pipeline landscape exhibits a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment. AstraZeneca and Daiichi Sankyo are among the leading companies driving innovation in the therapeutics segment with their respective pipeline drugs. The pipeline report
Cancer
According to a recent study published in Cancer Epidemiology, aspirin may play a role in reducing the risk of gastric cancer, but the dose-response relationship between aspirin use and gastric cancer risk remains unclear. The systematic review and meta-analysis analyzed data from cohort studies published between 2014 and 2024, involving
